Table 1 Properties of GPRC5D-targeted agents in MM
Author | Agent | Clinical Trial Identifier | Phase | Target | Mechanism | Cell source | References |
|---|---|---|---|---|---|---|---|
Sham Mailankody et al. | MCARH109 | NCT04555551 | 1 | GPRC5D | CAR-T | Autologous | [2] |
Jieyun Xia et al. | GPRC5D CAR-T | ChiCTR2100048888 | 2 | GPRC5D | CAR-T | Autologous | [3] |
Mingming Zhang et al. | OriCAR-017 | NCT05016778 | 1 | GPRC5D | CAR-T | Autologous | [4] |
Susan Bal et al. | BMS-986393 | NCT04674813 | 1 | GPRC5D | CAR-T | Autologous | [5] |
Ajai Chari et al. | Tal (JNJ-64407564) | NCT03399799/NCT04634552 | 1/2 | GPRC5D,CD3 | BiTE | Off-the-shelf | [6] |
Yaël C. Cohen et al. | Tal (JNJ-64407564) -DP or Tal-D versus DPd | NCT05455320 | 3 | GPRC5D,CD3 | BiTE | Off-the-shelf | [7] |
Carmelo Carlo-Stella et al. | RG6234 | NCT04557150 | 1 | GPRC5D,CD3 | BiTE | Off-the-shelf | [9] |
John Reiser | FT555 | – | Preclinical | GPRC5D,CD38 | CAR-NK | iPSCs master cell line | [11] |